TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36734148

Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36734154

Group type: EXPERIMENTAL
Intervention: Hypothetical breast cancer screening with potential harms and no reduction in mortality
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Understanding of the presented information
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Disbelief in the screening information
Number of subjects: 751
Study: 36734173

Group type: EXPERIMENTAL
Intervention: Ato-Trazo (atomoxetine plus trazodone)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 36734235

Group type: EXPERIMENTAL
Intervention: DAPT using cilostazol and either aspirin or clopidogrel (464 patients)
Number of subjects: 925

Group type: COMPARATOR
Intervention: SAPT using aspirin or clopidogrel alone (461 patients)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: DAPT using cilostazol
Number of subjects: 925

Group type: COMPARATOR
Intervention: SAPT using aspirin or clopidogrel
Number of subjects: 925
Study: 36734294

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) combined with low-dose apatinib (500 mg daily)
Number of subjects: 16
Study: 36734316

Group type: EXPERIMENTAL
Intervention: Wearable sensors during at-home visit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wearable sensors during laboratory visit
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: At-home visit experience
Number of subjects: 20
Study: 36734349

Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 908

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 908
Study: 36734351

Group type: EXPERIMENTAL
Intervention: Catheter-based structural heart interventions (left atrial appendage closure and percutaneous mitral valve repair)
Number of subjects: 47
Study: 36734354

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg per minute) with 0.9% NaCl infusion (750 mL/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo with 0.9% NaCl infusion (750 mL/h)
Number of subjects: 10
Study: 36734415

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood (UCB) therapy, infused once intravenously
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bayley Scale of Infant Development-II (BSID-II)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 13
Study: 36734509

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 24861
Study: 36734654

Group type: EXPERIMENTAL
Intervention: PTNS with PFE
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham PTNS with PFE
Number of subjects: 84
Study: 36734848

Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced MRI before treatment with liposomal irinotecan (nal-IRI)
Number of subjects: 27
Study: 36735048

Group type: EXPERIMENTAL
Intervention: High TILs concentration
Number of subjects: 372
Study: 36735057

Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risdiplam (after initial placebo)
Number of subjects: 0
Study: 36735117

Group type: EXPERIMENTAL
Intervention: Letrozole, everolimus, and carotuximab (letrozole 2.5 mg PO daily, everolimus 10 mg PO daily, carotuximab 15 mg/kg IV every 2 weeks)
Number of subjects: 15
Study: 36735143

Group type: EXPERIMENTAL
Intervention: Plan A (n=886)
Number of subjects: 1770

Group type: COMPARATOR
Intervention: Control video (n=884)
Number of subjects: 1770
Study: 36735261

Group type: EXPERIMENTAL
Intervention: Telephone coaching every 2 weeks for 6 months with home blood pressure monitoring.
Number of subjects: 316

Group type: COMPARATOR
Intervention: Usual care for hypertension.
Number of subjects: 316
Study: 36735263

Group type: EXPERIMENTAL
Intervention: Epicardial ICD
Number of subjects: 122

Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 122
Study: 36735287

Group type: EXPERIMENTAL
Intervention: ItFits-toolkit
Number of subjects: 456

Group type: COMPARATOR
Intervention: Implementation-as-usual (IAU)
Number of subjects: 456
Study: 36735296

Group type: EXPERIMENTAL
Intervention: BeT intervention (peer-led digital intervention over 3 months)
Number of subjects: 150
Study: 36735394

Group type: EXPERIMENTAL
Intervention: IMPACT-III questionnaire
Number of subjects: 84

Group type: COMPARATOR
Intervention: PedsQL
Number of subjects: 84
Study: 36735422

Group type: EXPERIMENTAL
Intervention: Single Incision Sling (SIS)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Midurethral Sling (TOT)
Number of subjects: 168
Study: 36735426

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 40
Study: 36735488

Group type: EXPERIMENTAL
Intervention: Rintodestrant
Number of subjects: 16
Study: 36735603

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36735635

Group type: EXPERIMENTAL
Intervention: Preoperative preparation-themed storybook (Elif Has Surgery) read by mother for 10 minutes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical routine (control group)
Number of subjects: 80
Study: 36735665

Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC)
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Dedicated service outlets (DSO)
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Combined IPC + DSO
Number of subjects: 2792

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 2792
Study: 36735745

Group type: EXPERIMENTAL
Intervention: GSK3772847 (10 mg/kg) administered intravenously at Weeks 0, 4, and 8
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo administered intravenously at Weeks 0, 4, and 8
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GSK3772847 (10 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 36735893

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 0
Study: 36735896

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day
Number of subjects: 58
Study: 36735911

Group type: EXPERIMENTAL
Intervention: rFVIIIFc (efmoroctocog alfa) 200 IU/kg per day until tolerization or maximum of 48 weeks
Number of subjects: 16
Study: 36735931

Group type: EXPERIMENTAL
Intervention: Balanced Solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 36735933

Group type: EXPERIMENTAL
Intervention: Multimodal Digital Care Program (DCP) for MSK pain management
Number of subjects: 9992
Study: 36735937

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) system with variable-loop circular catheter, at least 12 applications per vein; adenosine/isoproterenol administered to confirm entrance block.
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) system with variable-loop circular catheter.
Number of subjects: 226
Study: 36736112

Group type: EXPERIMENTAL
Intervention: Jitongning Tablet (JTNT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JTN fractions (JTN-2 and JTN-4)
Number of subjects: 0
Study: 36736209

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.6 μg/kg over 10 min, followed by continuous infusion of 0.5 μg/kg/h until 1 h before end of surgery)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 36736339

Group type: EXPERIMENTAL
Intervention: Increased adalimumab dose intervals to 40 mg every 3 weeks, further to every 4 weeks if in remission at week 24.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional dosing of adalimumab at 40 mg every 2 weeks.
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Increased adalimumab dose intervals (intervention group).
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional dosing of adalimumab (control group).
Number of subjects: 174
Study: 36736459

Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implanted in NICM patients
Number of subjects: 2429

Group type: COMPARATOR
Intervention: No ICD/CRT-D implanted in NICM patients
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implanted in ICM patients
Number of subjects: 2429

Group type: COMPARATOR
Intervention: No ICD/CRT-D implanted in ICM patients
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implanted in both NICM and ICM patients
Number of subjects: 2429

Group type: COMPARATOR
Intervention: No ICD/CRT-D implanted in both NICM and ICM patients
Number of subjects: 2429
Study: 36736724

Group type: EXPERIMENTAL
Intervention: Expression of CD125 on lung neutrophils in patients with COPD/emphysema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of IL-4 and IL-5 in airway fluid
Number of subjects: 0
Study: 36736781

Group type: EXPERIMENTAL
Intervention: Donor-derived (DD) virus-specific T cells
Number of subjects: 145

Group type: COMPARATOR
Intervention: Third-party (TP) virus-specific T cells
Number of subjects: 145
Study: 36736921

Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 751

Group type: COMPARATOR
Intervention: Hypofractionated radiation therapy
Number of subjects: 751

Group type: COMPARATOR
Intervention: Urban areas
Number of subjects: 751

Group type: COMPARATOR
Intervention: 75% less-deprived neighborhoods
Number of subjects: 751
Study: 36737079

Group type: EXPERIMENTAL
Intervention: Ellavi uterine balloon tamponade (UBT)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Training courses for obstetric staff
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Ellavi UBT
Number of subjects: 451
Study: 36737081

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention strategy including guidelines for PHM, training modules, risk assessment with TilThermometer, risk assessment with Downtown Fall Risk Index, and work environment mapping.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single intervention strategy including guidelines for PHM and work environment mapping.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both intervention strategies (multifactorial and single)
Number of subjects: 12
Study: 36737087

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 24905

Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 24905
Study: 36737097

Group type: EXPERIMENTAL
Intervention: Evening mobilisation delivered between 19:00 and 21:00
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 36737276

Group type: EXPERIMENTAL
Intervention: Maintenance oral etoposide
Number of subjects: 383

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Maintenance oral etoposide in platinum-refractory patients
Number of subjects: 383

Group type: COMPARATOR
Intervention: Observation in platinum-refractory patients
Number of subjects: 383
Study: 36737440

Group type: EXPERIMENTAL
Intervention: Inhibition of TET2 in NK cells of healthy donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azacytidine treatment in MDS patients
Number of subjects: 0
Study: 36737594

Group type: EXPERIMENTAL
Intervention: Different anti-anginal regimens
Number of subjects: 0
Study: 36737707

Group type: EXPERIMENTAL
Intervention: EMLA group
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Distraction group
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 299
Study: 36737725

Group type: EXPERIMENTAL
Intervention: Nature-based intervention (Open Sky School)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control group (standard curriculum)
Number of subjects: 2500
Study: 36737744

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm identifying patients for palliative care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care palliative care
Number of subjects: 42
Study: 36737825

Group type: EXPERIMENTAL
Intervention: Ezetimibe tablet (10 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ezetrol® (10 mg)
Number of subjects: 59
Study: 36737838

Group type: EXPERIMENTAL
Intervention: TENA SmartCare Change Indicator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36738088

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36738100

Group type: EXPERIMENTAL
Intervention: ASP8062 60 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 36738153

Group type: EXPERIMENTAL
Intervention: 3830 lead for LBBAP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simulated LBBAP use conditions
Number of subjects: 50
Study: 36738249

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G4
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Abbott Libre Pro
Number of subjects: 144
Study: 36738300

Group type: EXPERIMENTAL
Intervention: Hepatic MAIT cells in T2DM patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MAIT cells producing interferon-γ (IFN-γ) in T2DM patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MAIT cells producing tumour necrosis factor-α (TNF-α) in T2DM patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MAIT cells producing interleukin 17 (IL-17) in T2DM patients
Number of subjects: 29
Study: 36738333

Group type: EXPERIMENTAL
Intervention: TAK-164 (0.064 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TAK-164 (0.032-0.25 mg/kg)
Number of subjects: 31
Study: 36738358

Group type: EXPERIMENTAL
Intervention: Light Physical Activity (LPA)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 436
Study: 36738385

Group type: EXPERIMENTAL
Intervention: Cornerstone intervention (multi-component intervention with social worker and mentor)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cornerstone intervention (multi-component intervention)
Number of subjects: 56
Study: 36738630

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36738692

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interferential Current (IFC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 36738751

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 36738756

Group type: COMPARATOR
Intervention: Whole-breast irradiation (25 daily fractions of 50 Gy over 5 weeks with a supplemental boost of 10 Gy)
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: APBI using multicatheter brachytherapy (30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions over 5 days, or 50 Gy of pulsed-dose-rate brachytherapy over 5 days)
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 1328
Study: 36738762

Group type: EXPERIMENTAL
Intervention: Combination therapy (subcutaneous golimumab 200 mg at week 0, subcutaneous golimumab 100 mg at weeks 2, 6, and 10, intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks for 32 weeks)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Golimumab monotherapy (subcutaneous golimumab 200 mg at week 0 followed by subcutaneous golimumab 100 mg at week 2 and every 4 weeks thereafter for 34 weeks)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Guselkumab monotherapy (intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks thereafter for 32 weeks)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Golimumab monotherapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Guselkumab monotherapy
Number of subjects: 214
Study: 36738783

Group type: EXPERIMENTAL
Intervention: Delabeling penicillin allergy
Number of subjects: 0
Study: 36738867

Group type: EXPERIMENTAL
Intervention: Guideline-informed symptom management model targeting SPPADE symptoms
Number of subjects: 31886

Group type: EXPERIMENTAL
Intervention: SPPADE composite score
Number of subjects: 31886
Study: 36738927

Group type: EXPERIMENTAL
Intervention: Blood eosinophil cut points
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Addition of a second biomarker of type 2 inflammation
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment initiation
Number of subjects: 1074
Study: 36738928

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus pemetrexed and carboplatin
Number of subjects: 45
Study: 36738929

Group type: EXPERIMENTAL
Intervention: High-dose radiation (74 Gy)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Whole heart v5 and v30
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Matched cohort
Number of subjects: 458
Study: 36738930

Group type: COMPARATOR
Intervention: PCR tests
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: NGS-based genetic testing
Number of subjects: 636
Study: 36739136

Group type: EXPERIMENTAL
Intervention: Genotype-guided drug treatment (n=3342)
Number of subjects: 6944

Group type: COMPARATOR
Intervention: Standard care (n=3602)
Number of subjects: 6944

Group type: EXPERIMENTAL
Intervention: All patients receiving genotype-guided treatment (n=2923)
Number of subjects: 6944

Group type: COMPARATOR
Intervention: All patients receiving standard care (n=3270)
Number of subjects: 6944
Study: 36739258

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) and oral acetazolamide (OA) combination therapy (250mg twice daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) monotherapy
Number of subjects: 52
Study: 36739285

Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) or Tamoxifen + Aromatase Inhibitors (TAM-AI)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: GnRHa (Gonadotropin-Releasing Hormone Agonists)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 784
Study: 36739367

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 8 weeks
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study: 36739382

Group type: EXPERIMENTAL
Intervention: Primary data from emergency department patients (n=1442)
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Routine data from emergency department patients (n=9329)
Number of subjects: 1442
Study: 36739422

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 36739457

Group type: EXPERIMENTAL
Intervention: Increased numbers of platelet-derived microvesicles (PMVs) and monocyte-derived microvesicles (MMVs)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Platelet-derived microvesicles (PMVs) and monocyte-derived microvesicles (MMVs)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Correlation of PMVs and MMVs with radiation dose
Number of subjects: 208
Study: 36739508

Group type: EXPERIMENTAL
Intervention: Weekly attack frequency recording
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instantaneous attack frequency recording
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seasonal variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attack frequency variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline period of seven weeks
Number of subjects: 0
Study: 36739511

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 3507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3507
Study: 36739595

Group type: EXPERIMENTAL
Intervention: μ-opioid receptor agonists (MORAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MORAs
Number of subjects: 0
Study: 36739645

Group type: EXPERIMENTAL
Intervention: Eliglustat treatment
Number of subjects: 66
Study: 36739753

Group type: EXPERIMENTAL
Intervention: Behavioral activation for smoking cessation and the mitigation of PCWG (BAS+)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard smoking cessation counseling (SC)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: BAS+
Number of subjects: 288

Group type: COMPARATOR
Intervention: SC
Number of subjects: 288
Study: 36739866

Group type: EXPERIMENTAL
Intervention: Daprodustat (HIF-PHI)
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Conventional ESA treatment (standardized to weekly intravenous epoetin)
Number of subjects: 2964
Study: 36739879

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 133

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 133
Study: 36739961

Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 20
Study: 36740018

Group type: EXPERIMENTAL
Intervention: Standard enhanced recovery after surgery plus ice packs
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard enhanced recovery after surgery (control)
Number of subjects: 51
Study: 36740038

Group type: EXPERIMENTAL
Intervention: Usual care plus decision aid on CKM
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study: 36740094

Group type: EXPERIMENTAL
Intervention: Open surgical UEA
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Percutaneous UEA with closure devices
Number of subjects: 1098
Study: 36740638

Group type: EXPERIMENTAL
Intervention: Recurrent UTI Impact Questionnaire (RUTIIQ)
Number of subjects: 1983
Study: 36740691

Group type: EXPERIMENTAL
Intervention: Prehospital point-of-care ultrasound (POCUS)
Number of subjects: 214
Study: 36740708

Group type: EXPERIMENTAL
Intervention: One-step approach: laparoscopic common bile duct exploration plus laparoscopic cholecystectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Two-step approach: ERC plus sphincterotomy followed by laparoscopic cholecystectomy
Number of subjects: 150
Study: 36740715

Group type: EXPERIMENTAL
Intervention: chidamide
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: chidamide + JAK inhibitor ruxolitinib
Number of subjects: 28
Study: 36740814

Group type: EXPERIMENTAL
Intervention: Olorinab 50 mg
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 36740893

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 1151